Skip to main content
SpringerLink
Log in

Blasenkarzinom – Update

Was gab es neues auf dem Jahreskongress 2010 der Deutschen Gesellschaft für Urologie in Düsseldorf?

Bladder cancer update

What was new at the 2010 Annual Congress of the German Association of Urology in Düsseldorf?

  • Urologie aktuell
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Ein vorrangiges Ziel des nationalen Netzwerkes „Deutscher Forschungsverbund Blasenkarzinom e.V.“ ist es, eine Plattform zu bieten, auf der wissenschaftliche Aktivitäten im Bereich der Blasenkarzinomforschung gebündelt und kommuniziert werden. Einen fundierten Überblick über aktuelle Arbeiten auf diesem Forschungsgebiet bot die Jahrestagung der Deutschen Gesellschaft für Urologie vom 22. bis 25. September 2010 in Düsseldorf. In diesem Artikel werden einige der interessanten Beiträge zum Thema Blasenkarzinomforschung inhaltlich zusammengefasst und kommentiert. Ein Schwerpunkt wurde insbesondere auf das Urothelkarzinom im Bereich der Uropathologie und die präklinische Forschung gelegt.

Abstract

One of the principal objects of the scientific research network “German Bladder Cancer Network” is to consolidate research activities on bladder cancer. An overview about directions of current projects on this research topic was given at the annual meeting of the German Association of Urology in Düsseldorf from September 22 to 25 September 2010. As representatives of the“German Bladder Cancer Network” we summarize and comment on some of the most interesting projects on bladder cancer presented at this meeting. A special focus will be on current developments in the field of uropathology and on different aspects in preclinical research on bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Goebell PJ, Knowles MA (2010) Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 28(4):409–428

    PubMed  Google Scholar 

  2. Hoffmann AC,Wild P,Leicht C et al (2010) MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12(8):628–636

    CAS  PubMed  Google Scholar 

  3. Nawroth R, Hartmann A, Wild P et al (2010) EMMPRIN (CD147): A prognostic and potentially therapeutic marker in urothelial cancer. Pathologe 31(Suppl 2):251–254

    Article  PubMed  Google Scholar 

  4. Sidhu SS, Nawroth R, Retz M et al (2010) EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesis. Oncogene 29:4145–4156

    Article  CAS  PubMed  Google Scholar 

  5. Golshani R, Lopez L, Estrella V et al (2008) Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res 68(2):483–491

    Article  CAS  PubMed  Google Scholar 

  6. Lokeshwar VB, Estrella V, Lopez L et al (2006) HYAL1-v1, an alternatively spliced variant of HYAL1 hyaluronidase: a negative regulator of bladder cancer. Cancer Res 66(23):11219–11227

    Article  CAS  PubMed  Google Scholar 

  7. Lokeshwar VB, Gomez P, Kramer M et al (2008) Epigenetic regulation of HYAL-1 hyaluronidase expression. identification of HYAL-1 promoter. J Biol Chem 283(43):29215–29227

    Article  CAS  PubMed  Google Scholar 

  8. Girish KS, Kemparaju K, Nagaraju S et al (2009) Hyaluronidase inhibitors: a biological and therapeutic perspective. Curr Med Chem 16(18):2261–2288

    Article  CAS  PubMed  Google Scholar 

  9. Kramer MW, Golshani R, Merseburger AS et al (2010) HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol 57(1):86–93

    Article  CAS  PubMed  Google Scholar 

  10. Rink M, Chun FK, Minner S et al (2010) Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int (Epub ahead of print)

  11. Brunner A, Prelog M, Verdorfer I et al (2008) EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. J Clin Pathol 61(3):307–310

    Article  CAS  PubMed  Google Scholar 

  12. Heck MM, Gschwend JE, Retz M (2010) Update on chemotherapy for bladder cancer. Urologe A 49(10):1294–1300

    Article  CAS  PubMed  Google Scholar 

  13. Engelman JA (2009) Targeting PI3 K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550–562

    Article  CAS  PubMed  Google Scholar 

  14. Bamias A et al (1991) Intravesical administration of radiolabeled antitumor monoclonal antibody in bladder carcinoma. Cancer Res 51(2):724–728

    CAS  PubMed  Google Scholar 

  15. Bamias A, Keane P, Krausz T et al (1993) Intravesical administration of indium-111-labelled HMFG2 monoclonal antibody in superficial bladder carcinomas. Int J Cancer 54(6):899–903

    Article  CAS  PubMed  Google Scholar 

  16. Pfost B, Seidl C, Autenrieth M et al (2009) Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med 50(10):1700–1708

    Article  CAS  PubMed  Google Scholar 

  17. Huang B, Zhao J, Unkeless JC et al (2008) TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27(2):218–224

    Article  CAS  PubMed  Google Scholar 

  18. Conroy H, Marshall NA, Mills KH (2008) TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 27(2):168–180

    Article  CAS  PubMed  Google Scholar 

  19. Schulz WA (2006) Understanding urothelial carcinoma through cancer pathways. Int J Cancer 119(7):1513–1518

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Urologische Klinik und Poliklinik, Technische Universität München, Klinikum rechts der Isar, Ismaninger Straße 22, 81675, München, Deutschland

    R. Nawroth & M. Retz

  2. Pathologisches Institut, Universitätsklinikum Erlangen, Erlangen, Deutschland

    A. Hartmann & R. Stöhr

  3. Klinik für Urologie und Kinderurologie, Philipps-Universität Marburg, Marburg, Deutschland

    P.J. Olbert

  4. Klinik für Urologie und Urologische Onkologie, Medizinische Hochschule Hannover, Hannover, Deutschland

    A.S. Merseburger

  5. Institut für Pathologie, Universitätsklinikum Aachen, Aachen, Deutschland

    R. Knüchel

  6. Klinik für Urologie, Technische Universität Dresden, Dresden, Deutschland

    S. Füssel

Authors
  1. R. Nawroth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P.J. Olbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A.S. Merseburger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Stöhr
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Knüchel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Retz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Füssel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nawroth, R., Hartmann, A., Olbert, P. et al. Blasenkarzinom – Update. Urologe 50, 221–226 (2011). https://doi.org/10.1007/s00120-010-2486-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-010-2486-2

Schlüsselwörter

Keywords

Search

Navigation